-
Will Handbag Companies Be Hurt This Holiday Season?
Tuesday, June 30, 2015 - 10:33am | 331Read More...In a report published Tuesday, Cowen and Co analyst Oliver Chen said that the existing challenges in the Handbag sector may continue into the Holiday Season. The sector could continue to witness promo competition in US departmental stores, shift to CE spending, rise of athleisure and lack of...
-
Cowen CEO: 'You Can't Just Own Healthcare Broadly And Say It's Going To Work Out'
Monday, June 29, 2015 - 1:14pm | 341Read More...Jeffrey M. Solomon, president at Cowen Group Inc (NASDAQ: COWN) and CEO of Cowen and Company, was on Wall Street Week this Sunday to talk about the outlook of the biotech space overall. Here is what he had to say. Biotech, Reindustrialization Of America On whether he still sees healthcare and...
-
Offshore, 'Backlog Is King'
Thursday, June 18, 2015 - 12:23pm | 326Read More...A new report by Cowen and Company’s Scott Kirkwood focuses on the offshore engineering and construction business and what Cowen sees ahead for the segment in coming months. In the report, Cowen discussed its positive outlook for the industry. NOC/IOC Spending When it comes to offshore...
-
Cowen Downgrades Internap, Notes 'Execution Risk Too Much'
Friday, June 5, 2015 - 9:47am | 313Read More...In a report published Friday, Cowen and Company analyst Colby Synesael downgraded the rating on Internap Corp (NASDAQ: INAP) from Outperform to Market Perform, while maintaining the $11 price target. "Based on interviews with current/past employees we believe sales culture/customer service issues...
-
2 Analysts Discuss Why Express Scripts Could Lose From A Humana Takeover
Monday, June 1, 2015 - 10:10am | 522Read More...Shares of Humana Inc (NYSE: HUM) soared higher on Friday after reports surfaced that the company hired bankers to evaluate a sale of itself. Analysts at Stifel suggested a $230 to $240 per share price tag on any deal. On Monday, analysts at both Cowen and Raymond James discussed why a possible...
-
'Bizjet Product Transition' Led Cowen Analysts To Downgrade General Dynamics
Monday, May 25, 2015 - 12:09pm | 220Read More...In a report last week, Cowen analysts downgraded General Dynamics Corporation (NYSE: GD) from Outperform to Market Perform, with a price target of $153. The analysts expect the company to see a demand lull driven by product transition, which is likely to lead to a slowdown in earnings growth in...
-
Cowen Upgrades Panera, Says It Can 'Make Some Dough'
Tuesday, May 19, 2015 - 9:33am | 221Read More...In a report published Tuesday, Cowen and Company analysts upgraded the rating on Panera Bread Co (NASDAQ: PNRA) from Market Perform to Outperform. The price target was raised from $172 to $210. The analysts believe that there is limited downside to the stock. "We expect PNRA to be more efficient...
-
BlackBerry Price Target Just Cranked To $11 At Cowen
Thursday, May 14, 2015 - 10:02am | 259Read More...In a report published Thursday, Cowen and Company analysts maintained a Market Perform rating on BlackBerry Ltd (NASDAQ: BBRY), while raising the price target from $10 to $11 after investor meetings with company CFO James Yersh. Blackberry's ongoing transition from being a hardware-centric OEM to...
-
Analysts Met With UnitedHealth And Mylan Management; What Happened?
Monday, May 11, 2015 - 10:08am | 425Read More...Analyst meetings held by pharmaceutical companies throw light on strategic options in the industry. Following meetings with the management, Leerink analysts maintained an Outperform rating on Mylan NV (NASDAQ: MYL), with a price target of $67. Cowen and Co analysts maintained an Outperform rating...
-
Cowen: 'Not A Whole Lotta Love' In Whole Foods' Earnings Print
Thursday, May 7, 2015 - 12:31pm | 312Read More...In a report published Thursday, Cowen And Company analyst Jerry Gray maintained a cautious tone on Whole Foods Market, Inc. (NASDAQ: WFM) as a "significant" deceleration in store traffic resulted in sales to fall short of expectations in its second quarter. Whole Foods reported an earnings per...
-
Is BioMarin Still An Outperform At This Research Firm?
Friday, May 1, 2015 - 11:05am | 256Read More...In a report published Friday, Cowen and Company analysts maintained an Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), with a price target of $125. BioMarin reported its Q1 revenue at $203.3MM, in-line with consensus. Its non-GAAP EPS, at ($0.16), was significantly better than...
-
Cowen & Co: Nokia Goes 'Back To The Future In Wrong Direction'
Friday, May 1, 2015 - 10:38am | 166Read More...In a report published Friday, Cowen and Company analysts maintained a Market Perform rating on Nokia Corporation (NYSE: NOK), with a price target of $8. Nokia reported its 1Q15 revenues and EPS in-line with expectations. The results for the company's Networks segment were, however, quite...
-
Analyst: Sprouts 'Underperformance Creates Opportunity'
Friday, May 1, 2015 - 10:25am | 226Read More...In a report published Friday, Cowen and Company analysts maintained an Outperform rating on Sprouts Farmers Markets Inc (NASDAQ: SFM), with a target price of $40. Sprouts is expected to report robust 1Q results, driven mainly by strong new store productivity. The company's focus on price...
-
Does Anyone Care About Gilead's Beat, Guidance Boost?
Friday, May 1, 2015 - 10:22am | 236Read More...In a report published Friday, Cowen and Company analysts maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD), with a target price of $125. Gilead Sciences reported better-than-expected 1Q results, with the EPS upside driven by robust HCV revenues. The company's 1Q HCV sales, at $4.55...
-
IPO Outlook: CoLucid Offers Hope For Migraine Sufferers
Wednesday, April 29, 2015 - 8:20am | 1051Read More...Headache combatant CoLucid Pharmaceuticals (NASDAQ: CLCD) is three days from going public Friday, May 1. The biopharmaceutical company plans to raise $86 million through 5.4 million shares between $13 and $15. CoLucid has a market cap of $210 million and will list on the NASDAQ under the ticker...
